At Grove Biopharma, the R&D team is advancing a rational design approach to drug discovery. Their Bionic Biologics™ Platform assembles custom-engineered peptides to target intracellular protein-protein interactions into stable, potent, cell permeable therapeutics. By combining the precision of biologics with the efficiency of synthesizing small molecules, Grove accelerates lead generation and optimization.

Grove’s technology enables targeting key proteins involved in cancer and neurodegenerative diseases for which effective therapeutics have historically been difficult to develop. Their candidate molecules focus on important targets such as the Androgen Receptor splice variant, SHOC2 within the RAS/RAF pathway, the MYC-regulator WDR5, a Tau isoform relevant to Alzheimer’s Disease, and the Keap1-Nrf2 interaction associated with neurodegeneration. These programs have made significant progress and now represent some of the most advanced agents in their pipeline.